All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lefamulin Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Nabriva Therapeutics
Deal Size: $101.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement December 07, 2020
Details:
The restructured agreement provides for additional manufacturing collaboration and regulatory support [to be provided to Sinovant by Nabriva] that is expected to help expedite the delivery of XENLETA to patients in greater China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lefamulin Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
Findings underscore potential of XENLETA as a first-in-class pleuromutilin antibiotic for the IV and oral treatment of CABP in adults, including older patients with comorbidities who are at risk of poor outcomes
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lefamulin Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2020
Details:
In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lefamulin Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 16, 2020
Details:
Nabriva Therapeutics has received approval from Health Canada to market oral and intravenous (IV) formulations of XENLETA® (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tedizolid Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Sivextro
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 15, 2020
Details:
Under the terms of the agreement, Nabriva will procure SIVEXTRO from Merck & Co. Inc., Kenilworth, N.J., USA and be responsible for marketing, sales, and distribution of SIVEXTRO in the U.S. through December 31, 2023, with renewable three-year extensions.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lefamulin Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: WEP
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 06, 2020
Details:
Under the terms of the NPP, XENLETA will be made available in 2 formulations - 150mg injection for IV administration and 600mg oral tablets - using named patient or expanded access managed by WEP to enable healthcare professionals to access XENLETA to meet clinical needs.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
